{
    "symbol": "TRIB",
    "quarter": 3,
    "year": 2022,
    "date": "2022-12-15 14:11:09",
    "content": " In the comparative period, we had fair value adjustments on derivative balances related to the exchangeable notes, which is a financial income of just under $200,000, thus after tax was $8.9 million in Q3 2022, compared to a profit of $1.3 million in Q3 2021. Excluding our COVID-focused PCR products, Q3 2022 revenues of $19.2 million were marginally higher by 2% compared to Q3 2021 and were up 6% Q2 -- compared to Q2 2022."
}